{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:10:48Z","timestamp":1787893848309,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41395-018-0202-9","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T10:23:27Z","timestamp":1531823007000},"page":"1678-1688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report"],"prefix":"10.14309","volume":"113","author":[{"given":"Gary R.","family":"Lichtenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Salzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Langholff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Safdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Nissinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Taillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20210302","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MIB.0000000000001102","article-title":"The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease.","volume":"23","author":"Kammerlander","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R2-23-20210302","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gut.2006.108324","article-title":"A meta-analysis on the influence of inflammatory bowel disease on pregnancy.","volume":"56","author":"Cornish","year":"2007","journal-title":"Gut"},{"key":"R3-23-20210302","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.crohns.2009.10.001","article-title":"Pregnancy and IBD treatment: this challenging interplay from a patients perspective.","volume":"4","author":"Mountifield","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R4-23-20210302","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2036.2011.04794.x","article-title":"Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006.","volume":"34","author":"Bortoli","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R5-23-20210302","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ajg.2012.436","article-title":"Editorial: Are thiopurines and anti-TNFalpha agents safe to use in pregnant patients with inflammatory bowel disease?","volume":"108","author":"Sheibani","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R6-23-20210302","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.crohns.2009.03.008","article-title":"Appropriate management of special situations in Crohns disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): results of a multidisciplinary international expert panel-EPACT II.","volume":"3","author":"Mottet","year":"2009","journal-title":"J Crohns Colitis"},{"key":"R7-23-20210302","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/(SICI)1096-8628(19990917)86:3<242::AID-AJMG9>3.0.CO;2-U","article-title":"Maternal corticosteroid use and risk of selected congenital anomalies.","volume":"86","author":"Carmichael","year":"1999","journal-title":"Am J Med Genet"},{"key":"R8-23-20210302","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.reprotox.2003.10.007","article-title":"Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study.","volume":"18","author":"Gur","year":"2004","journal-title":"Reprod Toxicol"},{"key":"R9-23-20210302","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohns disease and rheumatoid arthritis.","volume":"99","author":"Katz","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R10-23-20210302","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.12936","article-title":"Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.","volume":"40","author":"Deepak","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-23-20210302","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1517\/14740338.2014.973399","article-title":"Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.","volume":"13","author":"Khan","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"R12-23-20210302","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/ibd.21368","article-title":"Successful use of infliximab for perianal Crohns disease in pregnancy.","volume":"17","author":"Chaparro","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R13-23-20210302","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohns disease: TREAT Registry.","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R14-23-20210302","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in Crohns disease: results from the TREAT Registry.","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R15-23-20210302","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohns disease: more than 5 years of follow-up in the TREAT Registry.","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R16-23-20210302","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Practice Parameters Committee of the American College of Gastroenterology. Management of Crohns disease in adults.","volume":"96","author":"Hanauer","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R17-23-20210302","first-page":"1091","article-title":"Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure.","volume":"20","author":"Broms","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R18-23-20210302","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/ajg.2012.430","article-title":"Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease.","volume":"108","author":"Casanova","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R19-23-20210302","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ibd.21154","article-title":"Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding.","volume":"16","author":"Gisbert","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"R20-23-20210302","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2016.10.013","article-title":"Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease.","volume":"152","author":"Mahadevan","year":"2017","journal-title":"Gastroenterology"},{"key":"R21-23-20210302","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0016-5085(14)60002-0","article-title":"2 Pregnancy outcomes amongst mothers with inflammatory bowel disease exposed to systemic corticosteroids: results of the PIANO registry.","volume":"146","author":"Lin","year":"2014","journal-title":"Gastroenterology"},{"key":"R22-23-20210302","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0016-5085(12)60561-7","article-title":"PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy.","volume":"142","author":"Mahadevan","year":"2012","journal-title":"Gastroenterology"},{"key":"R24-23-20210302","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/bdra.20735","article-title":"Updated national birth prevalence estimates for selected birth defects in the United States, 2004-2006.","volume":"88","author":"Parker","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R25-23-20210302","doi-asserted-by":"crossref","first-page":"13205","DOI":"10.3748\/wjg.v21.i47.13205","article-title":"Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.","volume":"21","author":"Androulakis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R26-23-20210302","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2036.2008.03648.x","article-title":"Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception.","volume":"27","author":"ODonnell","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R27-23-20210302","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto Consensus Statements for the management of inflammatory bowel disease in pregnancy.","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0202-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/00000434-201811000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:46:30Z","timestamp":1786542390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201811000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1038\/s41395-018-0202-9","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}